Tecentriq for Lung Cancer Outperforms Conventional Chemotherapy, Increases Survival in Phase 3 Study
News
Genentech recently announced positive results from the pivotal Phase 3 OAK study (NCT02008227) demonstrating that its cancer immunotherapy Tecentriq (atezolizumab) is more effective than the chemotherapy Taxotere for increasing patients’ median overall survival. The findings were presented at ... Read more